Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel
NASDAQ:BIIB

Biogen Q2 2026 Earnings Report

Biogen logo
$200.62 +2.88 (+1.46%)
Closing price 04:00 PM Eastern
Extended Trading
$200.46 -0.16 (-0.08%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Biogen EPS Results

Actual EPS
N/A
Consensus EPS
$3.13
Beat/Miss
N/A
One Year Ago EPS
N/A

Biogen Revenue Results

Actual Revenue
N/A
Expected Revenue
$2.46 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biogen Announcement Details

Quarter
Q2 2026
Date
7/29/2026
Time
Before Market Opens
Conference Call Date
Wednesday, July 29, 2026
Conference Call Time
8:30AM ET

Conference Call Resources

Biogen Earnings Headlines

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amneal Pharmaceuticals (AMRX), Alnylam Pharma (ALNY) and Biogen (BIIB)
July 23 at 3:21 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/BIIB/pressreleases/3423676/analysts-have-conflicting-sentiments-on-these-healthcare-companies-amneal-pharmaceuticals-amrx-alnylam-pharma-alny-and-biogen-biib/
Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know
July 23 at 3:21 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/ptc-therapeutics-ptct-report-negative-140029333.html
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
July 23 at 1:00 AM  |  Base Camp Trading (Ad)
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
July 22 at 1:17 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/analysts-estimate-biogen-inc-biib-140022640.html
Biogen And The Limitation Of The Tau Approach To Alzheimer's Disease
July 21 at 11:51 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4924005-biogen-stock-limitation-tau-approach-to-alzheimers-disease?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
Biogen: Balanced Risk-Reward Keeps Rating at Hold Amid MS Pressure and Uncertain New Asset Contributions
July 21 at 3:11 PM  |  tipranks.comhttps://www.tipranks.com/news/ratings/biogen-balanced-risk-reward-keeps-rating-at-hold-amid-ms-pressure-and-uncertain-new-asset-contributions-ratings-news?utm_source=marketbeat.com&utm_medium=referral
See More Biogen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biogen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biogen and other key companies, straight to your email.

About Biogen

Biogen (NASDAQ:BIIB) is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders. Biogen has also been active in the Alzheimer's field through collaborations with Eisai, bringing antibodies targeting amyloid pathology to market. In addition, Biogen has worked with partners on treatments for spinal muscular atrophy and other rare diseases, reflecting a mix of proprietary development and co-commercialization arrangements.

Biogen invests heavily in research and development, maintaining clinical-stage programs across a range of neuroscience indications and pursuing both small- and large-molecule approaches. The company operates through a combination of internal discovery, external collaborations, licensing deals and strategic acquisitions to expand its pipeline and commercial reach. Biogen is governed by an executive leadership team and a board of directors responsible for setting corporate strategy and overseeing its global operations.

View Biogen Profile
Earnings Tools